YorkBridge Wealth Partners’s Ligand Pharmaceuticals LGND Stock Holding History

YorkBridge Wealth Partners’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-131	Closed	-$9K	–	447
2019 Q2	$9K	Sell	131 -23	-15%	-$1.69K	﹤0.01%	584
2019 Q1	$12K	Sell	154 -45	-23%	-$3.41K	0.01%	552
2018 Q4	$17K	Hold	199	–	–	0.01%	495
2018 Q3	$34K	Sell	199 -30	-13%	-$4.52K	0.02%	401
2018 Q2	$30K	Sell	229 -72	-24%	-$8.03K	0.01%	433
2018 Q1	$31K	Buy	301 +35	+13%	+$3.46K	0.01%	425
2017 Q4	$25K	Sell	266 -3	-1%	-$260	0.01%	461
2017 Q3	$23K	Buy	269 +24	+10%	+$1.9K	0.01%	487
2017 Q2	$18K	Hold	245	–	–	0.01%	536
2017 Q1	$17K	Buy	245 +104	+74%	+$6.84K	0.01%	542
2016 Q4	$9K	Buy	+141	New	+$8.9K	0.01%	609

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

YorkBridge Wealth Partners's LGND Position: Q3 2019 in Review

YorkBridge Wealth Partners sold out of Ligand Pharmaceuticals (LGND) in Q3 2019, closing a stake of 131 shares — an estimated $9K sold.

YorkBridge Wealth Partners first reported a position in LGND in Q4 2016 and held it in 11 quarters. The position peaked at $34K in Q3 2018. 275 funds tracked by Wall St. Rank hold LGND as of Q3 2019.

YorkBridge Wealth Partners reported no remaining Ligand Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
YorkBridge Wealth Partners sold 131 Ligand Pharmaceuticals shares in Q3 2019, an estimated $9K.
YorkBridge Wealth Partners first reported a position in Ligand Pharmaceuticals in Q4 2016 and held it in 11 quarters.
YorkBridge Wealth Partners's Ligand Pharmaceuticals position peaked at $34K in Q3 2018.
275 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2019.

Based on YorkBridge Wealth Partners's 13F filing for Q3 2019, filed 21 Oct 2019.